Transcriptome

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

Retrieved on: 
星期四, 五月 9, 2024
AXIN1, Research, Partnership, Clostridioides difficile infection, Development, IND, DeepMind, NVIDIA, Biomarker, Drug discovery, Tempus, Pharmacokinetics, Map, ADME, Machine learning, Software, Appetite, Roche, APC, Infection, Neurofibromatosis type II, CCM, Transcriptome, Safety, Johnson & Johnson, Neuroscience, RNA, Artificial intelligence, FAP, Data science, Therapy, Translation, Chemistry, RBM39, Biology, Clinical trial, LILAC, NF2, University of Oxford, Recurrence, Computational biology, Hemangioma, Administration, Patient, Strategy, Trial of the century, Pharmaceutical industry

L(earnings) Call: Recursion will host a L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time.

Key Points: 
  • L(earnings) Call: Recursion will host a L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time.
  • Revenue: Total revenue was $13.8 million for the first quarter of 2024, compared to $12.1 million for the first quarter of 2023.
  • Research and Development Expenses: Research and development expenses were $67.6 million for the first quarter of 2024, compared to $46.7 million for the first quarter of 2023.
  • Net Loss: Net loss was $91.4 million for the first quarter of 2024, compared to a net loss of $65.3 million for the first quarter of 2023.

Shape Therapeutics RNAfix® Editing Platform Achieves >90% Editing in Mouse and Non-Human Primate Brain

Retrieved on: 
星期三, 五月 8, 2024
Brain, Transcriptome, AI, Rett syndrome, RNA, MD, Doctor of Philosophy, Cell, AAV, CNS, DNA, Patient, Gene, Society, Central nervous system, NHP, Annual general meeting, ADAR, Vaccine

SEATTLE, May 08, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, today presented data at the 27th American Society for Gene and Cell Therapy (ASGCT) Annual Meeting in Baltimore, MD showcasing the high therapeutic potential of its RNAfix platform in for the treatment of central nervous system (CNS) disorders.

Key Points: 
  • Potential therapeutic applications of RNAfix will be highlighted in Rett syndrome, Parkinson’s disease, and Alzheimer’s disease, showcasing a diversity of therapeutic mechanisms enabled by nucleotide-level precision RNA editing.
  • A superior safety profile will also be presented, with no significant off-target editing across the entire transcriptome.
  • The data presented at ASGCT highlight levels of editing in the CNS unparalleled by any other editing technology, unlocking vast therapeutic opportunities.
  • Importantly, the RNAfix platform leaves genomic DNA intact and does not require the delivery of foreign proteins with immunogenicity risks.

BioAro Announces a Medical and Computing Breakthrough by Launching the 'World's Fastest' Real-Time Genomic Software 'PanOmiQ'

Retrieved on: 
星期二, 四月 30, 2024
Irritable bowel syndrome, University, Transcriptome, Protein, AI, Metagenomics, Professor, Data format, Dubai World Trade Centre, Research, VCF, Artificial intelligence, Dysbiosis, Personalized medicine, Multiomics, DNA, Genome, Whole genome sequencing, Health, Biomarker, University of Patras, Genomics, Medicine, Quality of life, Longevity, IBS, Medical device

DUBAI, UAE, April 30, 2024 /PRNewswire/ -- BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human genome. With unparalleled speed, precision, and versatility, it promises to transform healthcare worldwide. The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.

Key Points: 
  • The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.
  • As the culmination of years of research and development, PanOmiQ stands as the world's fastest genomic analysis software to date.
  • "Turnaround time in genomic analysis is critical, and this is where PanOmiQ comes in with its unmatched speed and accuracy.
  • Please join us at the Precision Medicine Expo on May 9th, 2024, at the Dubai World Trade Centre, where BioAro will introduce PanOmiQ's groundbreaking capabilities.

Parse Biosciences Launches Single Cell Immune Profiling Products

Retrieved on: 
星期四, 五月 2, 2024
Research, Genetics, Health Technology, Stem Cells, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, BCR, Cell, American Association of Immunologists, AAI, Gene expression, Transcriptome, TCR, Vaccine

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ BCR and the expansion of its existing Evercode™ TCR product line.

Key Points: 
  • Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ BCR and the expansion of its existing Evercode™ TCR product line.
  • The new BCR solution and updates to the existing TCR product line expand Parse’s single cell portfolio and will enable researchers to study the immune repertoire at unprecedented resolution and scale.
  • Evercode BCR allows researchers to capture B cell receptor (BCR) sequences together with gene expression from the same cells.
  • “Scaling up cell counts and sample numbers are crucial for achieving impactful results in single cell immune profiling,” said Parse Biosciences co-founder and CTO Charlie Roco.

Parse Biosciences Launches Laboratory Automation Provider Program, Collaborates with Hamilton, Opentrons Labworks, SPT Labtech

Retrieved on: 
星期三, 四月 24, 2024
Research, Other Health, General Health, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Health Technology, Science, Biotechnology, Stem Cells, Health, Other Science, Cell, Neuroscience, RNA, Automation, Laboratory automation, Parsing, Transcriptome, Fine chemical

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has launched its Laboratory Automation Provider Program, enabling automation providers to readily support the adoption of Parse’s Evercode™ single cell products.

Key Points: 
  • Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has launched its Laboratory Automation Provider Program, enabling automation providers to readily support the adoption of Parse’s Evercode™ single cell products.
  • By combining powerful automation with the Parse Evercode platform, customers will have unprecedented access to high-throughput single cell sequencing, enabling them to rapidly generate insights for large-scale studies.
  • As key providers in the new Laboratory Automation Provider Program, Hamilton, Opentrons, and SPT Labtech will each collaborate with Parse to automate Parse’s Evercode Whole Transcriptome and Whole Transcriptome Mega workflows on their respective liquid handling platforms.
  • By joining with some of the industry's top automation providers, we are giving customers more extensive choices,” said Parse Biosciences co-founder and CEO Alex Rosenberg.

BioAro Announces a Medical and Computing Breakthrough by Launching the 'World's Fastest' Real-Time Genomic Software 'PanOmiQ'

Retrieved on: 
星期四, 四月 25, 2024
Irritable bowel syndrome, University, Transcriptome, Protein, AI, Metagenomics, Professor, Data format, Dubai World Trade Centre, AB, VCF, Research, Dysbiosis, Personalized medicine, Multiomics, Intelligence, DNA, Genome, Whole genome sequencing, Health, Biomarker, University of Patras, Genomics, Medicine, Quality of life, Longevity, IBS, Medical device

The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.

Key Points: 
  • The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.
  • As the culmination of years of research and development, PanOmiQ stands as the world's fastest genomic analysis software to date.
  • "Turnaround time in genomic analysis is critical, and this is where PanOmiQ comes in with its unmatched speed and accuracy.
  • Please join us at the Precision Medicine Expo on May 9th, 2024, at the Dubai World Trade Centre, where BioAro will introduce PanOmiQ's groundbreaking capabilities.

Lexogen launches end-to-end solutions for FFPE Transcriptomics

Retrieved on: 
星期三, 四月 10, 2024
Cancer, Drug design, Paraffin, Transcriptome, Small RNA, Tissue, Gene expression profiling, RNA, Research, Carcinogenesis, Illumina, Data analysis, Neoplasm, Biomarker, RNA-Seq, A-DNA, Vaccine

Drawing from years of experience with transcriptome sequencing from FFPE samples, Lexogen has developed new solutions and carefully optimized established technologies to provide convenient workflows from FFPE sample extraction to data analysis.

Key Points: 
  • Drawing from years of experience with transcriptome sequencing from FFPE samples, Lexogen has developed new solutions and carefully optimized established technologies to provide convenient workflows from FFPE sample extraction to data analysis.
  • Lexogen's FFPE Transcriptomics line includes the SPLIT One-Step FFPE RNA Extraction Kit, QuantSeq FFPE 3' mRNA-Seq Library Prep Kit for gene expression profiling, and CORALL FFPE Whole Transcriptome RNA-Seq with a seamlessly integrated gDNA removal step for whole transcriptome RNA-Seq.
  • The SPLIT One-Step FFPE RNA Extraction Kit allows easy and effective extraction of RNA from FFPE samples in less than 2 hours.
  • QuantSeq FFPE and CORALL FFPE are compatible with SPLIT One-Step FFPE RNA Extraction, include purification solutions and Unique Dual Indices, and come with complimentary data analysis on Lexogen's Kangooroo data analysis platform.

Lexogen launches end-to-end solutions for FFPE Transcriptomics

Retrieved on: 
星期三, 四月 10, 2024
Cancer, Drug design, Paraffin, Transcriptome, Small RNA, Tissue, Gene expression profiling, RNA, Research, Carcinogenesis, Illumina, Data analysis, Neoplasm, Biomarker, RNA-Seq, A-DNA, Vaccine

Drawing from years of experience with transcriptome sequencing from FFPE samples, Lexogen has developed new solutions and carefully optimized established technologies to provide convenient workflows from FFPE sample extraction to data analysis.

Key Points: 
  • Drawing from years of experience with transcriptome sequencing from FFPE samples, Lexogen has developed new solutions and carefully optimized established technologies to provide convenient workflows from FFPE sample extraction to data analysis.
  • Lexogen's FFPE Transcriptomics line includes the SPLIT One-Step FFPE RNA Extraction Kit, QuantSeq FFPE 3' mRNA-Seq Library Prep Kit for gene expression profiling, and CORALL FFPE Whole Transcriptome RNA-Seq with a seamlessly integrated gDNA removal step for whole transcriptome RNA-Seq.
  • The SPLIT One-Step FFPE RNA Extraction Kit allows easy and effective extraction of RNA from FFPE samples in less than 2 hours.
  • QuantSeq FFPE and CORALL FFPE are compatible with SPLIT One-Step FFPE RNA Extraction, include purification solutions and Unique Dual Indices, and come with complimentary data analysis on Lexogen's Kangooroo data analysis platform.

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
星期二, 四月 9, 2024
Shenzhen University, Molecular biology, Immunology, Nature Methods, Advanced technology, Proteome, Ageing, Speech, Genesis (journal), Data analysis, Southern Medical University, Neuroscience, Translation, Human Cell Atlas, Nature Communications, Biochemistry, Neurology, Communication, Transcriptome, Genetics, Research, Genome, Epigenome, Immunity, Microbiology, Metabolome, Diagnosis, Peking University, Health, Conference, GSA, Executive, Cancer, Fudan University, Reproduction, Biology, National academy, Zhejiang University, Medicine

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

BioSkryb Genomics to Present Novel Research on Tumor Heterogeneity at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
星期四, 三月 28, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Single-cell analysis, Disease, Transcriptome, Malignancy, Neoplasm, DNA, Genome, Workflow, AACR, Doctor of Philosophy, Phenotype, Genomics, SNV, Ageing, CNV, Mobile phone

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.

Key Points: 
  • BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.
  • “Tumor heterogeneity is a key challenge for researchers in the cancer research field.
  • As tumors evolve, subclones emerge with mutations that convey adaptive phenotypes, including resistance to therapies,” said Suresh Pisharody, CEO of BioSkryb.
  • “Our next generation single-cell technology gives scientists the tools to better understand the way tumors evolve with a comprehensive, scalable, and streamlined workflow.